BioMarin Pharmaceuticals Inc (BMRN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

BioMarin Pharmaceuticals ( BMRN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.1%. By the end of trading, BioMarin Pharmaceuticals fell 39 cents (-1%) to $38.27 on light volume. Throughout the day, 781,804 shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.4 million shares. The stock ranged in price between $38-$38.83 after having opened the day at $38.63 as compared to the previous trading day's close of $38.66. Other companies within the Drugs industry that declined today were: Cornerstone Therapeutics ( CRTX), down 21.2%, Pluristem Therapeutic ( PSTI), down 15.2%, Cell Therapeutics ( CTIC), down 13.2%, and Somaxon Pharmaceuticals ( SOMX), down 6.9%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $4.77 billion and is part of the health care sector. Shares are up 12.2% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

On the positive front, Neuralstem ( CUR), up 38%, AEterna Zentaris ( AEZS), up 21.8%, Aoxing Pharmaceutical Company ( AXN), up 16.7%, and Sunesis Pharmaceuticals ( SNSS), up 15.5%, were all gainers within the drugs industry with Johnson & Johnson ( JNJ) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half